

Discovery

CAMBRIDGE HEALTHTECH INSTITUTE'S
EIGHTH INTERNATIONAL

on TARGET

Targeting Diverse Pathways for Tomorrow's Therapeutics

November 2 - 4, 2010 World Trade Center Boston



Concurrent Tracks | November 2 - 3



Fourth Annual

HDAC Inhibitors



Fifth Annual

GPCR-Based Drug Discovery



Fifth Annual


Ion Channels as Therapeutic Targets



Inaugural

Targeting the PI3K Pathway

Concurrent Tracks | November 3 - 4



Eighth Annual

RNAi for Functional Screens



Fourth Annual

The Challenge of Developing Kinase Inhibitors



Third Annual

Diabetes Drug Discovery



Inaugural

New Ways to Tackle COPD and Other Chronic Pulmonary Diseases

DiscoveryOnTarget.com

EVENT FEATURES

- 600+ Participants
- 30 Exhibiting Companies
- Keynote Speakers
- Dedicated Poster Viewing Hours
- Breakout Discussion Groups
- 7 Short Courses (Nov. 1 + 3)
(See page 3 for details)

Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
T: 781.972.5400 • F: 781.972.5425
Toll-free in the U.S. 888.999.6288
www.healthtech.com

CORPORATE SPONSORS



CORPORATE SUPPORT SPONSORS



Conference-at-a-Glance

Hotel & Travel Information

MONDAY, NOVEMBER 1

11:30 am–12:00 pm	Registration
12:00 pm–3:00 pm	CONCURRENT Courses 1 and 4 (see page 3)
3:00 pm–3:30 pm	Registration
3:30 pm–6:30 pm	CONCURRENT Courses 2 and 3 and 4 (see page 3)
4:30 pm–6:30 pm	Main Conference Early Registration

TUESDAY, NOVEMBER 2

7:00 am–8:30 am	Registration and Morning Coffee
8:30 am–10:10 am	CONCURRENT TRACKS 1/2/3/4
10:10 am–10:40 am	Grand Opening Coffee Break in the Exhibit Hall
10:40 am–12:40 pm	CONCURRENT TRACKS 1/2/3/4
12:40 pm–2:20 pm	Luncheon Presentations or Lunch on Your Own
2:20 pm–3:25 pm	CONCURRENT TRACKS 1/2/3/4
3:25 pm–4:05 pm	Networking Refreshment Break in the Exhibit Hall
4:05 pm–5:05 pm	CONCURRENT TRACKS 1/2/3/4
5:05 pm–6:10 pm	Breakout Discussion Sessions
6:15 pm–7:15 pm	Happy Hour in the Exhibit Hall

WEDNESDAY, NOVEMBER 3

7:30 am–8:00 am	Registration and Morning Coffee
8:00 am–9:40 am	CONCURRENT TRACKS 1/2/3/4
9:40 am–10:40 am	Networking Coffee Break in the Exhibit Hall
10:40 am–12:10 pm	CONCURRENT TRACKS 1/2/3/4
12:10 pm	Close of Tracks 1/2/3/4
12:30 pm–1:30 pm	Registration
1:30 pm–3:10 pm	CONCURRENT TRACKS 5/6/7/8
3:10 pm–3:45 pm	Networking Refreshment Break in the Exhibit Hall
3:45 pm–5:45 pm	CONCURRENT TRACKS 5/6/7/8
6:00 pm–9:00 pm	Dinner Short Courses (see page 3)

THURSDAY, NOVEMBER 4

7:30 am–8:30 am	Continental Breakfast Breakout Discussion Sessions
8:35 am–10:10 am	CONCURRENT TRACKS 5/6/7/8
10:10 am–10:55 am	Networking Coffee Break in the Exhibit Hall
10:55 am–12:40 pm	CONCURRENT TRACKS 5/6/7/8
12:40 pm–1:55 pm	Luncheon Presentations or Lunch on Your Own
1:55 pm–3:00pm	CONCURRENT TRACKS 5/6/7/8
3:00 pm–3:40 pm	Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)
3:40 pm–5:10 pm	CONCURRENT TRACKS 5/6/7/8
5:10 pm	Close of Discovery on Target

CONFERENCE VENUE:

World Trade Center

200 Seaport Blvd.
Boston, MA 02210

CONFERENCE HOTEL:

Seaport Hotel

One Seaport Lane
Boston, MA 02210
Phone: 617-385-4514 Fax: 617-385-4505

Discounted Room Rate: \$235 s/d

Discounted Cut-off Date: September 24, 2010

Please visit our website to make your reservations online or call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early

Flight Discounts:

To receive a 5% or greater discount on all American Airline flights please use one of the following methods:

- Call 1-800-433-1790 use Conference code A48H0AP
- Go online www.aa.com enter Conference code A48H0AP in promotion discount box
- Contact Wendy Levine, Great International Travel
1-800-336-5248 ext. 137

Car Rental Discounts:

Special discount rentals have been established with Hertz for this conference. Please use one of the following methods:

- Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0001
- Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0001

Sponsorship Opportunities

Sponsorship packages give you prime access to hard to reach end-users. Speak directly to prospective clients and make an impact for your company!

Agenda Presentations

Speak to a captive audience about your latest product or service. This sponsorship includes a 15-minute podium presentation within the scientific agenda as well as exhibit space, onsite branding and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon Presentations

These presentations include a 30-minute podium presentation with a 15-minute Q&A session. Invite session attendees to enjoy breakfast or lunch on your company's behalf while you give your talk.

Invitation-Only VIP Dinner

Sponsor will hand pick its top

Other Networking and Promotional Opportunities:

- Branded badge lanyards
- Exhibit hall reception
- Chair drops of company literature
- Branded padfolios
- Branded tote bags
- Tote bag inserts

Exhibitor Information

Exhibitors at the Discovery OnTarget will enjoy facilitated networking opportunities with more than 600 high-level decision-makers. Speak face to face with prospective clients and showcase your latest product, service or solution.

For more information please contact:

Jon Stroup, Manager, Business Development

781-972-5483

jstroup@healthtech.com

prospects and invite them to a night of networking at a top local venue. Enjoy a night of discussion and collaboration in a casual atmosphere. CHI will work closely with you to develop an invitation format and invitee list.

Focus Groups

CHI will gladly provide you the opportunity of running a focus group on-site at Discovery OnTarget. This exclusive gathering can be useful to conduct market research, gather feedback on a new product idea and gather marketing intelligence from industry experts on a specific topic.

User Group Meetings

Co-locate your user group meeting with Discovery OnTarget. CHI will help market the event, manage logistical operations, develop the agenda, and more. CHI can handle the entirety of the meeting, or aspects of your choosing.

NOVEMBER 1, 2010

Course 1 12:00 pm – 3:00 pm Allosteric Modulators of GPCRs

Topics to be Covered

- Introduction to theory, types and kinetics of allosteric modulators
- Screening and assays for small molecule allosteric modulators of GPCRs
- Examples of non-small molecule allosteric modulators of GPCRs
- Case study of discovery and development of a GPCR allosteric modulator with a focus on optimization challenges
- Q&A panel session with the instructors

Course Instructors:

Scott Kuduk, Ph.D., Senior Research Fellow, Medicinal Chemistry, Merck & Co.

Shaun R. Stauffer, Ph.D., Research Assistant Professor of Pharmacology, Director of Medicinal Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center

Annette Gilchrist, Ph.D., Assistant Professor, Midwestern University, Chicago College of Pharmacy

Frederick Jones, M.D., President and Chief Executive Officer, Anchor Therapeutics (panelist only)

Lunch provided, courtesy of Anchor Therapeutics

Course 2 3:30 pm – 6:30 pm

Structure-Based Design of Ion Channel – Linked Receptors

Topics to be Covered

- High –Throughput screening of channel inhibitors
- Automated patch clamp for screening
- NMR for structure – based design
- Current technologies

Designing a QPatch Assay; Help for Beginners

Dayne Okuhara, Ph.D., Scientist, Synta Pharmaceuticals, Corp.

Additional Instructors to be Announced

NOVEMBER 3, 2010

Course 5 8:00 am – 12:00 pm

Best Practices for Setting Up Effective RNAi Screens

The course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their input on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.

Course Instructors:

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

Namjin Chung, Ph.D., Senior Research Investigator, Applied Genomics, Bristol-Myers Squibb Co.

Marc Ferrer, Ph.D., Team Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health

Serena Silver, Ph.D., RNAi Screening Projects Group Leader, Broad Institute at MIT

Course 6 6:00 pm – 9:00 pm DINNER COURSE In vivo Discovery and Validation Using RNAi

In vivo experiments with RNAi are proving to be more complex and intricate than those done *in vitro*. This course is designed to provide experimental and technical details involving the design and use of such RNAi-based *in vivo* screens. Questions surrounding the choice and use of appropriate reagents and animal models, criteria for experimental design and quality control, immunogenic and off-target effects, and other important issues will be discussed in extensive detail. The course will also go over the challenges surrounding efficient delivery of siRNA or shRNA molecules into the cell, tissue uptake and retention, success of systemic and local delivery, and instructors will offer guidance and alternatives based on their expertise and experiences. These *in vivo*-based RNAi screens cover a diverse range of applications such as, screens for functional analysis of cellular pathways and moieties, for understanding the biology of a disease, for validation

of drug targets, and many others. Scientists involved in these areas of research or those looking to learn more about how these screens are effectively designed and used are encouraged to participate.

Course Instructors:

Annie Conery, Ph.D., Director, *C. elegans* Screening Core, Department of Molecular Biology, Massachusetts General Hospital

Siew Ho, Ph.D., Senior Principal Scientist, Applied Biotechnology, Bristol-Myers Squibb Co.

Lizabeth Perkins, Ph.D., Associate Professor of Pediatrics/Genetics, Pediatric Surgical Research Laboratories, Massachusetts General Hospital; Director, Transgenic RNAi Project at Harvard Medical School

8:00 pm – 8:30 pm Dinner Presentation KinaseSwitch and RNAi Technology Platforms

Sponsored by
TACONIC

Kenneth D. Campbell, Ph.D., Associate Director, Scientific Commercial Development, Taconic

Novel *in vivo* technology platforms have recently been developed and validated, which enable investigators to gain greater insights into drug and target-related disease mechanisms. TaconicArtemis' transgenic RNAi mouse models are innovative, commercially available additions to the aforementioned technologies. Inducible/reversible RNAi technology enables gene knockdown in all tissues of the body and can be induced as well as reversed, providing an optimal surrogate for therapeutic drug action. The use of transgenic RNAi technology to validate gene function in relevant disease models will be presented.

Course 7 6:00 pm – 9:00 pm DINNER COURSE Assessing Cardio Safety of Diabetes Drug Candidates

This workshop is designed to help scientists understand and discuss their diabetes drug development work in the context of the cardio-safety guidelines issued by the FDA in 2008 and recent high-profile FDA decisions related to currently marketed diabetes drugs.

- Historical perspective on how we've gotten to this point in safety assessment
- Basics of micro- v. macrovascular complications of diabetes (DCCT and UKPDS trials)
- Glucose control v. CV outcome: lessons from large outcome trials such as Accord/Advance/VADT
- Discussion of the new FDA Guidance and regulatory expectations in detail
- Lessons learned from the Avandia cardio-safety issues
- Case studies and interactive discussion with course participants around the challenge of conducting clinical trials in reasonable amount of time and cost

Instructors:

G. Alexander Fleming, M.D., President and CEO, Kinexum (formerly responsible for diabetes drugs, Division of Metabolic and Endocrine Drug Products, FDA)

Michael Trautmann, M.D., Senior Medical Fellow, Lilly Diabetes, Eli Lilly & Company

*Separate registration required.

CHI's Intro-Net: Networking at its Best!

Maximize Your Experience On-site at Discovery On Target!

CHI's **INTRO-NET** offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is available only to registered session attendees of this event. Registered conference attendees will receive more information on how to access the Intro-Net in the weeks leading up to the event!

Add a short course to your conference registration and Save \$100!

Stay Connected!

Join the Discovery on Target group on





HDAC Inhibitors

Tracking Pre-Clinical and Clinical Progress in Oncology, CNS, Inflammation and More

TUESDAY, NOVEMBER 2

7:00 am Conference Registration and Morning Coffee

EXPLORING EFFICACY AND SPECIFICITY OF HDAC INHIBITORS

8:30 Chairperson's Opening Remarks

James Bradner, M.D., M.Sc., Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

8:40 What's Next for HDAC Inhibitors - Better Combinations or Better Specificity?

Sriram Balasubramanian, Ph.D., Senior Director, Translational Research, Pharmacyclics, Inc.

9:10 Proteomic Approach to Define the Anti-Tumor Effects of an HDACi as Single Agent or in Combination Treatment

Alfredo Budillon, M.D., Ph.D., Chief, Experimental Pharmacology Unit, National Cancer Institute, G. Pascale, Italy

9:40 Augmenting the Efficacy of HDAC Inhibitors

Joya Chandra, Ph.D., Associate Professor of Pediatrics Research, Children's Cancer Hospital, M.D. Anderson Cancer Center, University of Texas

10:10 Grand Opening Coffee Break in the Exhibit Hall

10:40 Non-Peptide Macrocyclic Histone Deacetylase Inhibitors for Targeted Cancer Treatment

Yomi Oyelere, Ph.D., Assistant Professor of Chemistry and Biochemistry, Georgia Institute of Technology

11:10 Sensitive HTS Assays to Interrogate Histone Deacetylase (HDAC) & Sirtuin Enzymes

Andrew Niles, Senior Research Scientist, Promega

Sponsored by



Promega

11:40 New HDAC Inhibitors for Hematologic Malignancies

James Bradner, M.D., M.Sc., Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

12:10 pm Using AR-42 to Better Understand the Mechanism of HDAC Inhibition

Craig Hofmeister M.D., Assistant Professor of Medicine, Multiple Myeloma Clinical Lead, The Ohio State University Comprehensive Cancer Center

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

UNDERSTANDING THE CELLULAR EFFECTS OF HDACs

2:20 Chairperson's Remarks

Stanley Spence, Ph.D., Executive Director, Preclinical Safety Assessment, Novartis Institutes of Biomedical Research

2:25 Inherent Epigenetic Make-Up of Cancer Cells and their Predisposition to HDACi Sensitization

France Carrier, Ph.D., Associate Professor, Radiation Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland

2:55 Pre-Clinical Cardiac Risk Assessment of Histone Deacetylase Inhibitors: An Integrated Assessment

Stanley Spence, Ph.D., Executive Director, Preclinical Safety Assessment, Novartis Institutes of Biomedical Research

3:25 Networking Refreshment Break in the Exhibit Hall



4:05 KEYNOTE PRESENTATION: Function, Mechanism of Action, and Regulation of HDACs

Edward Seto, Ph.D., Chairman, Department of Molecular Oncology, H. Lee Moffitt Cancer Center

5:05 Interactive Breakout Discussion Groups

6:15 – 7:15 Happy Hour in the Exhibit Hall Sponsored by 

WEDNESDAY, NOVEMBER 3

7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

PROGRESS IN PRE-CLINICAL AND CLINICAL DEVELOPMENT OF HDACi

8:00 Chairperson's Opening Remarks

Sriram Balasubramanian, Ph.D., Senior Director, Translational Research, Pharmacyclics, Inc.

8:10 Phase II Clinical Development of Resminostat, a Novel Oral Histone Deacetylase Inhibitor in Neoplastic Disease

Stefan W. Henning, Ph.D., Project Manager, Development, 4SC AG

8:40 Pre-Clinical and Clinical Development of HDACi to Reverse Hormone Resistance in Breast Cancer

Pamela Munster, M.D., Associate Professor, Department of Medicine, University of California, San Francisco

9:10 Clinical Update on Panobinostat

Murielle Mueller, Assistant Director, Global Medical Affairs, Novartis

9:40 Networking Coffee Break in the Exhibit Hall

10:40 Targeting of HDAC Inhibitors to Monocytes and Macrophages: Potential in Cancer and Inflammatory Disease

Scott Cuthill, PhD, Associate Director Business Development, Chroma Therapeutics Ltd

11:10 A Dose-escalating Clinical Trial Evaluating the Combination of Suberoylanilide Hydroxamic Acid with Capecitabine Using a New Weekly Dose Regimen for Advanced Breast Cancer

Maysa Abu-Khalaf, M.B.B.S., Assistant Professor, Medical and Gynecology Oncology, Yale Comprehensive Cancer Center

11:40 Development of a Selective HDAC Inhibitor for Friedreich's Ataxia

James Rusche, Ph.D., Senior Vice President, Research & Development, Repligen Corporation

12:10 pm Close of Conference

Suggested Event Package
(November 1-4)

November 1
Pre-Conference Short Courses

November 2-3
Conference

November 3-4
Conference

HDAC Inhibitors

OR

Kinase Inhibitors

RNAi for Functional Screens

Lead Sponsoring
Publications

Pharmaceutical
Review

Bio-IT World

International
DrugDiscovery

TheScientist
MAGAZINE OF THE LIFE SCIENCES

nature

Science
AAAS

GPCR-Based Drug Discovery

Designing and Optimizing Therapies Targeting GPCRs



TUESDAY, NOVEMBER 2

7:00 am Conference Registration and Morning Coffee

GPCR'S IN DISEASE

8:30 Chairperson's Opening Remarks

8:40 Discovery of Ligands for the Hydroxy-Carboxylate Receptors GPR109a and GPR109b

Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals

9:10 Comparative evaluation of Allosteric Inhibitors for the Chemokine Receptor CCR1

Annette Gilchrist, Ph.D., Assistant Professor, Midwestern University, Chicago College of Pharmacy

9:40 Drug Discovery of GPCR (SIP1 or IP)-Targeted Candidate (preliminary title)

John Gatfield, Ph.D., Senior Laboratory Head, Cardiovascular and Fibrosis Biology, Actelion Pharmaceuticals, Ltd.

10:10 Grand Opening Coffee Break in the Exhibit Hall

PROBING SIGNALING COMPLEXITIES

10:40 Employing Homogenous Time-Resolved FRET to Probe the Quaternary Organization of GPCRs

Graeme Milligan, Ph.D., Professor, University of Glasgow

11:10 Accelerating Lead Optimization of Drug Candidates Through Iterative Screening and Modeling

Alan H. Katz, Ph.D., Chief Scientific Officer, Hudson Robotics, Inc.



11:25 Harnessing the Benefits of GPCR Signaling Complexity with the CellKey® System

Catherine Parrish, Application Scientist, Molecular Devices, Inc.



11:40 Use of Encoded Library Technology for Discovery of Small Molecule Ligands to GPCRs

David Israel, Ph.D., Director of Cell and Molecular Technologies, Molecular Discovery Research Boston, GlaxoSmithKline

12:10 pm Mechanism of Allosteric Modulation by CXCR4 Pepducins

Stephen Hunt III, Ph.D., Senior Vice President, Discovery Research, Anchor Therapeutics

12:40 Luncheon Presentation Accelerate Your Research with OriGene's GPCR Resource: cDNA Clones, shRNAs, and Stable Cell Lines

Xuan Liu, Ph.D., Director of Marketing, OriGene

Sponsored by



NEW APPROACHES TO GPCR DRUG DISCOVERY

2:20 Chairperson's Remarks

2:25 Case Study of GPCR-Based Drug Discovery Using High Content Screening

Lisa Smith, M.S., Scientist, In Vitro Pharmacology, Merck Research Labs

2:55 Intrinsic Reporters of Cell Signaling: High Content Drug Profiling and Characterization of Functional Heterodimers
Stuart Sealfon, Ph.D., Prof. & Chair, Neurology, Mount Sinai Sch. of Med.

3:25 Networking Refreshment Break in the Exhibit Hall

4:05 Optimized 7TMR Assays Forgoing Stable Cell Lines
Robert S. Ames, Ph.D., Director, Cellular Targets/Biological Reagents and Assay Development, GlaxoSmithKline

4:35 Using Thermostabilised Receptors (StaRs) to Generate Therapeutic Antibodies to GPCRs

Catherine Hutchings, Ph.D., Antibody Project Leader, Heptares Therapeutics, Ltd.

5:05 Interactive Breakout Discussion Groups

6:15 – 7:15 Happy Hour in the Exhibit Hall

Sponsored by sophion

WEDNESDAY, NOVEMBER 3

7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

GPCR STRUCTURE

8:00 Chairperson's Opening Remarks

Sid Topiol, Ph.D., Research Fellow, Computational Chemistry, Lundbeck Research USA, Inc

8:10 Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism

Jonathan M. Moore, Ph.D., Senior Director, Structural Biology, Vertex Pharmaceuticals Incorporated

8:40 KEYNOTE PRESENTATION: All-Atom Molecular Dynamic Simulation of an Opsin-Transducin Complex in a Membrane Bilayer

Thomas Sakmar, M.D., Professor, Molecular Biology and Biochemistry, Rockefeller University

9:40 Networking Coffee Break in the Exhibit Hall

10:40 Structural Basis for Ligand-Induced Pathway-Biased Signaling in 7TM receptors

Thue W. Schwartz, Ph.D., Professor, The Novo-Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen

11:10 Enabling Structure-Based Compound Design of GPCRs Through Biophysical Characterization

Mike Hanson, Ph.D., Associate Director Structural Biology, Receptos, Inc.

11:40 Impact of Recent X-Ray Structure Determinations on Structure-Based Drug Design for GPCRs and other CNS Targets

Sidney Topiol, Ph.D., Chief Scientific Officer, 3D-2Drug; Research Fellow, Computational Chemistry, Lundbeck Research USA, Inc

12:10 pm Close of Conference

Suggested Event Package (November 1-4)

November 1
Pre-Conference Short Courses

Allosteric Modulators of GPCRs (SC1)

Structure-Based Design of Ion Channel - Linked Receptors (SC2)

AND

November 2-3
Conference

GPCR-Based Drug Discovery

November 3-4
Conference

Kinase Inhibitors

Diabetes Drug Discovery

OR

Sponsoring Publications



Genome Technology



Ion Channels as Therapeutic Targets

Discovering and Optimizing Drug Development Candidates

TUESDAY, NOVEMBER 2

7:00 am Conference Registration and Morning Coffee

KEYNOTE PRESENTATIONS

8:30 Chairperson's Opening Remarks



8:40 Ion Channels: Targets of Therapy and the Subject of Safety

Gregory J. Kaczorowski, Ph.D., President, CEO, Kanalis Consulting, L.L.C.; Adjunct Professor, Physiology and Pharmacology, New Jersey Medical School; Adjunct Professor, Physiology and Biophysics, Robert Wood Johnson Medical School



9:25 Evolving Approaches to Ion Channel Drug Discovery in Big Pharma

Laszlo Kiss, Ph.D., Senior Research Fellow, Merck Research Laboratories

10:10 Grand Opening Coffee Break in the Exhibit Hall

ION CHANNEL MODULATORS

10:40 Denufosal for Cystic Fibrosis: An R&D Case Study of an Investigational GPCR Agonist that Functions as an Ion Channel Regulator

Tomas Navratil, Ph.D., Director, Pulmonary Scientific Affairs, R&D, Inspire Pharmaceuticals

11:10 The IonWorks Barracuda System, a 384-Well Automated Electrophysiology Platform for Ligand- or Voltage-Gated Ion Channels

Karen Cook, M.S., Application Scientist, Automated Electrophysiology, Molecular Devices, Inc.

Sponsored by



11:40 Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis

Fredrick VanGoor, Ph.D., Scientist II, Vertex Pharmaceuticals

12:10 pm Modulation of Sodium Channel Currents by Physiological Concentration of Thyroid Hormone L-Thyroxine

James Cao, Ph.D., Staff Scientist, Signal transduction, Ordway Research Institute

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

2:20 Chairperson's Remarks

NOVEL TARGETS

2:25 Kv1.3: A New Class of Therapeutic Target for Type 2 Diabetes

Chuan-Chu Chou, Ph.D., Research Fellow, Merck

2:55 Ion Channels as Novel Targets in Cancer

Mustafa Djamgoz, Ph.D., Professor of Cancer Biology, Cell & Molecular Biology, Imperial College London

3:25 Networking Refreshment Break in the Exhibit Hall

4:05 Discovery and Characterization of Novel Chloride-Channel Inhibitors

Merritt Maduke, Ph.D., Associate Professor, Stanford University

4:35 Identification and Optimization of Novel Thienopyrimidines as Inhibitors of the Kv1.5 Voltage-Gated Potassium Channel

Basil Hartzoulakis, Ph.D., Principal Scientist, Medicinal Chemistry, Xention Ltd.

5:05 Interactive Breakout Discussion Groups

6:15 – 7:15 Happy Hour in the Exhibit Hall

Sponsored by sophion

WEDNESDAY, NOVEMBER 3

7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Chairperson's Opening Remarks

NOVEL APPROACHES

8:10 ROMK as a Novel Diuretic Target

Jerod S. Denton, Ph.D., Assistant Professor, Anesthesiology and Pharmacology, Vanderbilt University Medical Center

8:40 Kidney Potassium Channels: Targets for Anti-Hypertensives?

Birgit T. Priest, Ph.D., Senior Research Fellow, Merck Research Laboratories

9:10 Regulation of Epithelial Sodium Channels by External Cues

Thomas Kleyman, M.D., Chief, Renal-Electrolyte Division, Professor, Medicine, Cell Biology and Physiology, and Pharmacology, University of Pittsburgh

9:40 Networking Coffee Break in the Exhibit Hall

SAFETY RISKS

10:40 Preclinical Evaluation of Safety risks for Cardiac Ion Channels: hERG and Beyond

Gul Erdemli, M.D., Ph.D., Head of Ion Channel Group, Novartis

11:10 Improving Lead Generation

11:40 Expert Panel Discussion

12:10 pm Close of Conference

Suggested Event Package
(November 1-4)

November 1
Pre-Conference Short Courses

AND { Allosteric Modulators of GPCRs (SC1)

Structure-Based Design of Ion Channel - Linked Receptors (SC2)

November 2-3
Conference

OR { Ion Channels as Therapeutic Targets

November 3-4
Conference

OR { Kinase Inhibitors

Diabetes Drug Discovery

Inaugural

November 2-3, 2010



Targeting the PI3K Pathway

Inhibiting Signaling of PI3K, Akt and mTOR

TUESDAY, NOVEMBER 2

7:00 am **Conference Registration and Morning Coffee**

IDENTIFYING AND DEVELOPING NOVEL INHIBITORS

8:30 **Chairperson's Opening Remarks**

Kevin Liu, Ph.D., Senior Principle Scientist, Pfizer, Inc.

8:40 **Design and Development of Novel, Isoform-Selective PI3K Inhibitors for the Treatment of Immune-Inflammatory Diseases and Cancer**

Stephen J. Shuttleworth, Ph.D., FRSC CChem, CSO, Karus Therapeutics, Ltd.

9:10 **From PI3K/mTOR Dual Inhibitors to PI3K and mTOR Selective Inhibitors**

Kevin Liu, Ph.D., Senior Principle Scientist, Pfizer, Inc.

9:40 **Genome-Wide RNAi Screening Identifies New Components of the mTOR Signaling Pathway in Pancreatic Cancer Cells**

Angela Papageorgiou, Ph.D., Research Fellow, Massachusetts General Hospital and Harvard Medical School

10:10 **Grand Opening Coffee Break in the Exhibit Hall**

10:40 **The Effect of Mutual Suppression of the PI3K/Akt/ mTor Pathway by Combining Rapamycin and Perifosine**

Noopur Raje, M.D., M.B., Assistant Professor, Medicine, Massachusetts General Hospital, Harvard Medical School

Sponsored by

11:10 **PI3K (PIK3CA) Mutation Analysis: Challenges in Companion Diagnostic Development**

Dr. David M. Jackson, Ph.D., Senior Director, Pharma Business Development, QIAGEN



11:25 **Sponsored Presentation (Opportunity Available)**

11:40 **Talk Title to be Announced**

Laurent Salphati, Pharm.D., Ph.D., Scientist, Drug Metabolism and Pharmacokinetics, Genentech

12:10 pm **EXPERT PANEL DISCUSSION: Targeting the PI3K Pathway - Which are Promising Approaches?**

12:40 **Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own**

FROM PRE-CLINICAL TO CLINICAL SUCCESS

2:20 **Chairperson's Remarks**

2:25 **Development of the Clinical Stage Dual mTOR-PI3K Inhibitor SF1126**

Joseph R. Garlich, Ph.D., CSO, Semafore Pharmaceuticals

2:55 **Pre-Clinical Characterization of Novel mTORC1 and mTORC2 Inhibitors**

Shripad Bhagwat, Ph.D., Research Investigator, Biochemical and Cellular Pharmacology, OSI Pharmaceuticals, Inc.

3:25 **Networking Refreshment Break in the Exhibit Hall**

4:05 **Palomid 529, a dual TORC1/TORC2 Allosteric Inhibitor of the PI3K/Akt/mTOR Pathway**

David Sherris, Ph.D., President and CEO, Paloma Pharmaceuticals, Inc.

4:35 **Discovery of Novel Multiplex PI3 Kinase Inhibitors for the Treatment of Cancer**

Dapeng Qian, M.D., Ph.D., Senior Director, Drug Discovery, Progenics Pharmaceuticals, Inc.

5:05 **Interactive Breakout Discussion Groups**

6:15 – 7:15 **Happy Hour in the Exhibit Hall**

Sponsored by sophion

WEDNESDAY, NOVEMBER 3

7:15 am **Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee**

EXPLORING DIFFERENT PATHWAY OPTIONS

8:00 **Chairperson's Opening Remarks**

8:10 **Feedback from Roundtable Moderators**

8:40 **PI3Kalpha Isoform Selective Inhibitors For Targeting Human Cancer Genetics**

Michael Martin, Ph.D., Vice President, Preclinical Development, Intellikine, Inc.

9:10 **PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers**

Ensar Halilovic, Ph.D., Novartis Institutes for BioMedical Research, Inc.

9:40 **Networking Coffee Break in the Exhibit Hall**

10:40 **Talk Title to be Announced**

Juswin der Singh, Ph.D., CSO, Avila Therapeutics

11:10 **Allosteric Akt Inhibitors**

Hans E. Huber, Ph.D., Senior Investigator, Cancer Research, Merck and Co., Inc. (tentative)

11:40 **Identification of PKI-179 as a Potent and Orally Efficacious PI3 Kinase Inhibitor**

Zecheng Chen, Ph.D., Principal Research Scientist, Pfizer, Inc.

12:10 pm **Close of Conference**

Suggested Event Package
(November 1-4)

November 1

Pre-Conference Short Courses

AND

Allosteric Modulators of GPCRs (SC1)

Structure-Based Design of Ion Channel - Linked Receptors (SC2)

November 2-3

Conference

Targeting the PI3K Pathway

November 3-4

Conference

OR

Kinase Inhibitors

Diabetes Drug Discovery

Reasons You Should Present Your Research Poster at **Discovery on Target 2010:**

- Your poster will be exposed to over 600 delegates to leaders from top pharmaceutical, biotech, academic and government institutes
- Receive \$50 off your registration fee
- Your poster abstract will be included in our conference materials

Please register for the meeting and we will send you abstract submissions instructions via email. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, accepted and registration paid in full by September 22, 2010.





RNAi for Functional Screens

Effectively Utilizing RNAi as a Tool for Screening Cellular Pathways and Drug Targets

WEDNESDAY, NOVEMBER 3

12:30 -1:30 pm Conference Registration

SEEKING NOVEL DRUG TARGETS

1:30 Chairperson's Remarks

Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

1:40 A Physiologically-Relevant Assay System for Amyloid Precursor Protein Target Identification

Shane Marine, Ph.D., Senior Research Biochemist, Merck Research Laboratories, Department of Automated Biotechnology

2:10 An Image-Based siRNA Screen for Kinase Genes That are Important for Cancer Cells to Adapt to Hypoxia

Steven Haney, Ph.D., Associate Fellow, Applied Quantitative Genotherapeutics, Pfizer BioTherapeutics and Bioinnovation Center, Pfizer Inc.

2:40 RNAi Screen With a High-Throughput qRT-PCR Assay Readout for Novel Target Identification

Namjin Chung, Ph.D., Senior Research Investigator, Applied Genomics, Bristol Myers Squibb Co.

3:10 Networking Refreshment Break in the Exhibit Hall

3:45 Synthetic Lethal siRNA Screens Using Pre-Clinical Compounds

Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research

4:15 Strategies for Improving RNAi Screening Success: Using a Ubiquitin-EGFP Assay to Identify Druggable Genes Required for Proteasome Function

James Goldmeyer, Ph.D., Field Application Scientist, Thermo Scientific Genomics, Dharmacon RNAi Technologies

4:45 Translating Human Genetic Discoveries to Novel Targets and Therapeutics

Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

5:15 PANEL DISCUSSION: The Current Fate of Drug Targets Being Uncovered by RNAi Screens

Moderator: Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

5:45 End of Day

6:00 pm – 9:00 pm Conference Short Course*

DINNER COURSE

In vivo Discovery and Validation Using RNAi

See details on page 3. * Separate registration required.

Sponsored by
Thermo
SCIENTIFIC

9:10 RNAi, mRNA Biogenesis and Genome-Wide Drug Modifier Screens

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

9:40 Functional Genomic Strategies for Defining Host-Pathogen Interactions

Abraham Brass, M.D., Ph.D., Investigator, Ragon Institute of Massachusetts General Hospital, Harvard Medical School

10:10 Networking Coffee Break in the Exhibit Hall

10:55 RNAi Screening in Cancer Cell Lines: Synthetic Lethals and Oncogene Modulators

Joanna Holbrook, Ph.D., Protein Dynamics DPU, Cancer Research, Oncology R&D, GlaxoSmithKline Plc.

11:25 Patent Considerations and Trends in RNAi

Steven L. Highlander, Ph.D., Partner, Intellectual Property, Fulbright & Jaworski LLP

James Coburn, President/CEO, Harbor Consulting

12:25 RNAi Screening in the Human Muscle Line, RD1: A Functional Genomics Screen to Enhance Insulin Signaling

James Fischer, Ph.D., Senior Scientist, Compound Safety Prediction, WW Medicinal Chemistry, Pfizer, Inc.

12:55 Luncheon Presentation: Introducing "PhenoTac™" – An Efficient, Comprehensive Platform for Genetic Target Validation

Kenneth D. Campbell, Ph.D., Associate Director, Scientific Commercial Development, Taconic

Sponsored by
Taconic

EXPLORING HIGH-THROUGHPUT, HIGH-CONTENT RNAi SCREENS

1:55 Chairperson's Remarks

Shane Marine, Ph.D., Senior Research Biochemist, Merck Research Laboratories, Department of Automated Biotechnology



2:00 KEYNOTE PRESENTATION: Applying High-Throughput RNAi to Empower Systems Biology

Spyro Mousses, Ph.D., Vice President, Office of Innovation; Director, Center of BioIntelligence, Translational Genomics Research Institute

3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40 Quantitative Multi-Parametric Image Analysis to Determine Off-Target Effects

Marc Bickle, Ph.D., Head HT-Technology Development Studio, Max Planck Institute of Molecular Cell Biology and Genetics

4:10 High-Content Assay Development in Macrophages: Applications for Host-Pathogen Screening

Iain Fraser, Ph.D., Investigator, Program in Systems Immunology and Infectious Disease Modeling (PSIIM) National Institute of Allergy and Infectious Diseases National Institutes of Health

4:40 Forcing Glioblastoma Tumor Initiating Cells to Differentiate: An High Throughput, High Content Imaging Screen to Target Transcription Factors and GTPases

Milan Chheda, M.D., Post-doctoral Fellow, Dana Farber Cancer Institute, Broad Institute, and Memorial Sloan-Kettering Cancer Center

5:10 Close of Conference

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups

DIVERSIFYING FUNCTIONAL GENOMIC SCREENS

8:35 Chairperson's Opening Remarks

Marc Ferrer, Ph.D., Team Leader, NIH Chemical Genomics Center /National Human Genome Research Institute, National Institutes of Health

8:40 A Comprehensive Strategy From RNAi Screening, Through Validation, Genomic Analysis, Comparative Biology to Biological Target

Alex Bishop, Ph.D., Assistant Professor, Cellular and Structural Biology, University of Texas Health Science Center, San Antonio

Suggested Event Package
(November 1-4)

November 3

Conference Short Courses

Best Practices for Setting Up Effective RNAi Screens (SC5)

Dinner Course: In vivo Discovery and Validation Using RNAi

AND

November 2-3

Conference

GPCR-Based Drug Discovery

Ion Channels as Therapeutic Targets

OR

November 3-4

Conference

RNAi for Functional Screens

The Challenge of Developing Kinase Inhibitors

Targeting Selectivity, Specificity, and Novel Therapeutic Areas



WEDNESDAY, NOVEMBER 3

12:30 - 1:30 pm Conference Registration

KINASE INHIBITOR CHEMISTRY

- 1:30 Chairperson's Remarks**
- 1:40 Scaffold-Based Inhibitor Design Strategies Targeting Type II and Allosteric Sites: Future Beyond the Kinase Domain**
Hariprasad, Vakayalapati, M. Pharm., Ph.D., Chief Scientist, Medicinal Chemistry, Center for Investigational Therapeutics, Huntsman Cancer Institute
- 2:10 Fragments and Drug Discovery for Kinase Targets**
Roderick E. Hubbard, Ph.D., Senior Fellow, Research, Vernalis, Ltd.
- 2:40 Scaffold Hopping as a Method to Diversify and Generate New Leads for p38**
Kristofer Moffett, Ph.D., Senior Scientist, Chemistry, Ansaris, a division of Locus Pharmaceuticals, Inc.
- 3:10 Networking Refreshment Break in the Exhibit Hall**
- 3:45 Fragment Replacement for Lead Generation**
Roger Armen, Ph.D., Scientist, Department of Chemistry, University of Michigan
- 4:15 Sponsored Presentation (Opportunity Available)**
- 4:45 Talk Title to be Announced**
Yogesh Sabnis, Ph.D., Computational Chemist, Pfizer Ltd.
- 5:15 Expert Panel Discussion: How much of a Challenge is the Selectivity of Kinase Inhibitors?**
- 5:45 End of Day**

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups

OPTIMIZING LEADS

- 8:35 Chairperson's Opening Remarks**
- 8:40 Feedback from Roundtable Breakout Discussions**
- 9:10 Hit to Lead Optimization of B-Raf Kinase Inhibitors**
Ariamala Gopalsamy, Ph.D., Principal Scientist III, Pfizer, Inc.
- 9:40 Talk Title to be Announced**
Jan Hoflack, Ph.D., Vice President Discovery, Oncodesign
- 10:10 Networking Coffee Break in the Exhibit Hall**

SAFETY CONSIDERATIONS

- 10:55 Selected Poster Presentation**
- 11:25 Small Molecule Kinase Inhibitor Promiscuity: Translating Kinase Selectivity Into Early Safety Guidance**
Andrew Olaharski, Ph.D., DABT, Head of Early Safety Representatives, Hoffmann-La Roche; Nutley, NJ
- 11:55 Expert Panel Discussion: Tackling the Fine Line between Safety and Toxicity**
- 12:25 pm Sponsored Presentation (Opportunity Available)**
- 12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own**

NOVEL TARGETS AND THERAPEUTIC AREAS

- 1:55 Chairperson's Remarks**
- 2:00 Discovery of Novel, Potent Non-ATP Competitive MK2 Inhibitors**
Dong Xiao, Ph.D., Principal Scientist, Chemical Research Department, Merck Research Laboratories
- 2:30 Development of a Novel Kinase Inhibitors for Treatment of Neuroinflammation**
Anumantha Kanthasamy, Ph. D., Distinguished Professor and W. E. Lloyd Chair, Biomedical Sciences, Iowa State University
- 3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall**
- 3:40 ARQ 197, A Novel and Selective Inhibitor of the Human c-Met receptor Tyrosine Kinase with Antitumor Activity**
Dennis S. France, Ph.D., Vice-President, Molecular Oncology, ArQule, Inc.
- 4:10 Developing Novel Kinase Inhibitors for Neurodegenerative Diseases**
Min Liu, Ph.D., Instructor, Neurology, Brigham and Women's Hospital
- 4:40 Expert Panel Discussion: The Challenge of Finding New Therapeutic Areas - Are there Still Bigger Fish to Catch?**
- 5:10 Close of Conference**

Suggested Event Package
(November 1-4)

November 1

Pre-Conference Short Courses

AND { Allosteric Modulators of GPCRs (SC1)
Structure-Based Design of Ion Channel - Linked Receptors (SC2)

November 2-3

Conference

{ Targeting the PI3K Pathway
HDAC Inhibitors

November 3-4

Conference

{ Kinase Inhibitors
Diabetes Drug Discovery

Web
Partners

BioSpace.com
Global leading for the life sciences

CanBiotech
Biotechnology Portal
& B2B Marketplace

channels

Diabetes
Portal
diabetesscience.net

genomeweb

GPCR
Portal
gproteins.com

GoingToMeet.com
THE MOST COMPREHENSIVE ONLINE CONFERENCE DIRECTORY

hum-molgen.org
central gateway to
HUMAN MOLECULAR GENETICS

Ion Channel
Portal
ionchannel.org

www.PharmCast.com
- Pharmaceutical Internet -

SelectScience.net
The Scientists' Choice

DiscoveryOnTarget.com

Email: reg@healthtech.com Phone: 781-972-5400 Fax: 781-972-5425



Diabetes Drug Discovery

Targeting Diabetes with Novel Therapeutics

WEDNESDAY, NOVEMBER 3

12:30 - 1:30 pm Conference Registration
DIABETES DRUG DEVELOPMENT CHALLENGES

1:30 pm Chairperson's Remarks
 Rebecca Taub, M.D., Senior Vice President, R&D, VIA Pharmaceuticals



1:40 KEYNOTE PRESENTATION:
Future Treatment of Diabetes: Integrating Perspectives From Bench, Bedside, and Beyond
 Jorge Plutzky, M.D., Director, The Vascular Disease Prevention Program, Cardiovascular Division, Brigham and Women's Hospital; Associate Professor, Harvard Medical School

2:25 OPENING PANEL: CLINICAL DEVELOPMENT CONSIDERATIONS
 Moderator: Rebecca Taub, M.D., Senior VP, R&D, VIA Pharmaceuticals

- What will the ideal future regimen look like?
- Combination therapies?
- Different regimens for different patient populations?
- How much and at what point in development is some CV risk acceptable?

Panelist:
 Michael Trautmann, M.D., Senior Medical Fellow, Lilly Diabetes, Eli Lilly & Company

3:10 Networking Refreshment Break in the Exhibit Hall
TARGETING G PROTEIN COUPLED RECEPTORS TO MODULATE INSULIN LEVELS

3:45 Glucagon Receptor Antagonists (tentative title)
 Michael Miller, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Merck

4:15 Economic and Scientific Considerations for High Throughput and Selective Drug Screening in Diabetes - The Value of Using Human Tissue *Sponsored by*
 Kenneth L. Brayman, M.D., Ph.D., FACS, Principal Scientific Advisor, Betapro, LLC 

4:45 GPR39, A Novel Target for Type-2 Diabetes and Obesity
 Birgit Holst, Ph.D., Associate Professor, University of Copenhagen

5:15 Targeting Entero-Endocrine 7TM Chemo-Sensors for Metabolic Diseases
 Thue W. Schwartz, Ph.D., Professor, The Novo-Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen

5:45 End of Day

6:00 pm - 9:00 pm Conference DINNER SHORT COURSE*
Assessing Cardio Safety of Diabetes Drug Candidates
 See details on page 3. * Separate registration required.

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups
NEW DIABETES PATHWAYS AND DRUG CANDIDATES

8:35 Chairperson's Opening Remarks
 Andrew G. Swick, Ph.D., Nutrition Research Institute, Department of Nutrition, University of North Carolina at Chapel Hill

8:40 11beta-HSD1 Inhibition in Type 2 Diabetes
 Reid Huber, Ph.D., Executive Director, Clinical Development, Incyte Corp.

9:10 Separating Mitogenic and Metabolic Activities of FGF19
 Yang Li, Ph.D., Scientific Director, Metabolic Disorders, Amgen, Inc.

9:40 Use of a Small Molecule Inhibitor of Macrophage Migration Inhibitory Factor is Therapeutic in Treatment of Non-Insulin-Dependent Diabetes Mellitus
 Thais Sielecki, Ph.D., VP, Preclinical Development, R&D, Cytokine

10:10 Networking Coffee Break in the Exhibit Hall
10:55 Systems Approaches to Modeling Diabetes within Pfizer
 Avijit Ghosh, Ph.D.; Senior Principal Scientist; Department of Pharmacokinetics, Dynamics and Metabolism; Pfizer Global Research and Development

11:25 Update on a New Diabetes Target (tentative title)
 Andrée R. Olivier, Ph.D., Biomarker Experimental Medicine Leader, Metabolic and Vascular Diseases, Roche

11:55 PR119 Agonists for the Treatment of Diabetes
 Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc.

12:25 pm Sponsored Presentation (Opportunity Available)
12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

TARGETING THE PANCREAS AND OBESITY

1:55 Chairperson's Remarks
 Michael Trautmann, MD, Senior Medical Fellow, Exenatide GBD Team, Eli Lilly

2:00 Regenerating Pancreatic Islet Cells
 Rohit Kulkarni, M.D., Ph.D., Associate Professor, Joslin Diabetes Center, Harvard

2:30 Pre-Clinical Development of Peptide Therapeutic that Stimulates Pancreas Regeneration
 H. Joseph Reiser, CEO, CureDM

TARGETING THE PANCREAS AND OBESITY (continued)

3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40 Contrave: Weight Loss and Improvements in A1C in Patients with Type 2 Diabetes
 Holly Maier, Ph.D., Medical Affairs, Orexigen Therapeutics, Inc.

4:10 Enteropeptidase: A Gene Associated to a Lean Human Phenotype as a Novel Target for the Treatment Obesity and Type II Diabetes
 Itzik Harosh, Ph.D., Founder and CEO, Obetherapy

4:40 Preclinical Models for Quantifying Pancreatic Beta Cell Regulation
 Alokesh Duttaroy, Ph.D., Investigator, Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Inc.

5:10 Close of Conference

Suggested Event Package
 (November 1-4)

November 3
Dinner Short Course

Assessing Cardio Safety of Diabetes Drug Candidates (SC7)

November 2-3
Conference

Ion Channels as Therapeutic Targets

GPCR-Based Drug Discovery

November 3-4
Conference

Diabetes Drug Discovery



New Ways to Tackle COPD and Other Chronic Pulmonary Diseases

Probing Novel Drug Targets, Disease Models, Biomarkers and Treatment Options

WEDNESDAY, NOVEMBER 3

12:20 - 1:30 pm Conference Registration

NEW PATHWAYS AND MOLECULAR TARGETS FOR TREATING COPD

1:30 Chairperson's Remarks



1:40 KEYNOTE PRESENTATION: Overcoming Steroid Insensitivity in COPD

Ian Adcock, Ph.D., Professor, Respiratory Cell & Molecular Biology, Airways Disease Section, National Heart and Lung Institute and Faculty of Medicine, Imperial College, London

2:40 Autophagy in COPD

Augustine Choi, M.D., Department of Medicine, Harvard Medical School and Chief, Pulmonary and Critical Care Medicine, Brigham And Women's Hospital

3:10 Networking Refreshment Break in the Exhibit Hall

3:45 Presentation to be Announced

4:15 Sponsored Presentation (Opportunity Available)

4:45 A Decoy CXCL8 Shows Potent Anti-Inflammatory Activity in Murine Lung Inflammation Models of COPD

Andreas J. Kungl, Ph.D., CSO, ProtAffin Biotechnology AG

5:15 PANEL DISCUSSION: What Are the Biggest Challenges in COPD Over the Next Decade?

Moderator: Augustine Choi, M.D., Department of Medicine, Harvard Medical School and Chief, Pulmonary and Critical Care Medicine, Brigham and Women's Hospital

5:45 End of Day

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups

INSIGHTS INTO PATHOGENESIS OF COPD

8:35 Chairperson's Opening Remarks

8:40 NK Cell Function in COPD: Functions in Disease Progression and Viral Exacerbations

Michael Borchers, Ph.D., Assistant Professor, Department of Environmental Health, University of Cincinnati

9:10 Role of RTP801 and Stress-Sensing in Cigarette Smoke-Induced Lung Injury

Rubin M. Tuder, M.D., Director, Program in Translational Lung Research, Division of Pulmonary and Critical Care Medicine, University of Colorado Denver, School of Medicine

9:40 Therapeutic Potential of JBT-1 in Lung Injury and COPD

Jeanine D'Armiesto, M.D., Ph.D., Associate Professor, Department of Medicine, Columbia University

10:10 Networking Coffee Break in the Exhibit Hall

10:55 Oxidative Stress and Pathogenesis of COPD: Emerging Therapeutic Targets

Irfan Rahman, Ph.D., Associate Professor, Department of Environmental Medicine, University of Rochester Medical Center

11:25 PANEL DISCUSSION: Emerging Therapies for COPD: Clinical Needs, Commercial Potential, Research and Development Challenges

Moderator: Tim Joslin, Managing Director, Europe, Defined Health

Panelists:

John Efthimiou BSc MD FRCP, Chief Development and Medical Officer, ProtAffin Biotechnologie AG

Stephen G. Farmer, Ph.D., Global Product Strategy Director, Respiratory Business Franchise, Novartis Pharma AG

12:25 pm Sponsored Presentation (Opportunity Available)

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

PRE-CLINICAL AND CLINICAL UPDATE ON TARGETS FOR COPD

1:55 Chairperson's Remarks

2:00 Clinical Results in COPD: Use of ACE Inhibitors

David W. Moskowitz, M.D., Chairman, CEO and Chief Medical Officer, GenoMed, Inc.

2:30 Targeting a Novel Pathway of Pulmonary Inflammation in COPD: Proteases, Products, and Therapeutics

Amit Gaggar, M.D., Ph.D., Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham

3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40 Title to be Announced

Paul Newbold PhD., Senior Director Clinical Science, Clinical Development Respiratory, MedImmune

4:10 Development of an Oral Vaccine for Treating COPD

4:40 PANEL DISCUSSION: Use of New Models and Biomarkers for Understanding COPD

5:10 Close of Conference

Suggested Event Package
(November 1-4)

November 1
Pre-Conference Short Courses

November 2-3
Conference

November 3-4
Conference

OR { Ion Channels as Therapeutic Targets
Targeting the PI3K Pathway

New Ways to Tackle COPD and Other Chronic Pulmonary Diseases

HOW TO REGISTER: Online: www.DiscoveryOnTarget.com

✉ Email: reg@healthtech.com

☎ Phone: 781-972-5400 Option 1

📠 Fax: 781-972-5425

REGISTRATION INFORMATION

Mr. Ms. Mrs. Dr. Prof.

Name _____
Job Title _____ Div./Dept. _____
Company _____
Address _____
City/State/Postal Code _____
Country _____
Telephone _____

How would you prefer to receive notices from CHI? Email: Yes No Fax: Yes No

Email* _____ Fax _____

*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference presenter materials, conference updates, networking opportunities and requested eNewsletters.

Key Code DOT F

SHORT COURSE PRICING

Add a Short Course to your Conference Registration and **SAVE \$100**

	Commercial	Academic, Government, Hospital-affiliated
Single Short Course	<input type="checkbox"/> \$695	<input type="checkbox"/> \$395
Two Short Courses	<input type="checkbox"/> \$995	<input type="checkbox"/> \$595
Three Short Courses	<input type="checkbox"/> \$1295	<input type="checkbox"/> \$795
Registered Conference Delegates SAVE \$100	<input type="checkbox"/> -\$100	<input type="checkbox"/> -\$100

REQUIRED: Please select the short course(s) you will be attending
November 1

- SC1 Allosteric Modulators of GPCRs
 SC2 Structure-Based Design of Ion Channel-Linked Receptors

- November 3**
 SC5 Best Practices for Setting Up Effective RNAi Screens
 SC6 *In vivo* Discovery and Validation Using RNAi
 SC7 Assessing Cardio Safety of Diabetes Drug Candidates

CONFERENCE PRICING

SINGLE CONFERENCE PACKAGE

Includes access to one (1) conference (excludes short courses)

Advance Registration Deadline until September 17, 2010

Registrations after September 17, 2010 and on-site

Commercial	Academic, Government, Hospital-affiliated
<input type="checkbox"/> \$1,445	<input type="checkbox"/> \$775
<input type="checkbox"/> \$1,645	<input type="checkbox"/> \$875

REQUIRED: Please select the 1 conference you will attend

November 2-3

- Track 1: HDAC Inhibitors
 Track 2: GPCR-Based Drug Discovery **or**
 Track 3: Ion Channels
 Track 4: PI3K Pathways

November 3-4

- Track 5: RNAi for Functional Screening
 Track 6: Kinase Inhibitors
 Track 7: Diabetes Drug Discovery
 Track 8: COPD

MULTI CONFERENCE PACKAGE

Includes access to two (2) conferences (excludes short courses)

Advance Registration Deadline until September 17, 2010

Registrations after September 17, 2010 and on-site

Commercial	Academic, Government, Hospital-affiliated
<input type="checkbox"/> \$2,345	<input type="checkbox"/> \$1,025
<input type="checkbox"/> \$2,495	<input type="checkbox"/> \$1,095

REQUIRED: Please select the 2 conferences you're most likely to attend

November 2-3

- Track 1: HDAC Inhibitors
 Track 2: GPCR-Based Drug Discovery **and**
 Track 3: Ion Channels
 Track 4: PI3K Pathways

November 3-4

- Track 5: RNAi for Functional Screening
 Track 6: Kinase Inhibitors
 Track 7: Diabetes Drug Discovery
 Track 8: COPD

POSTER DISCOUNT

REGISTER 3 - 4th IS FREE

Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply. Please reproduce this registration form as needed.

GROUP DISCOUNTS AVAILABLE! Special rates are available for multiple attendees from the same organization.

For more information on group discounts contact **David Cunningham at 781-972-5472**

I cannot attend but would like to purchase the Discovery On Target conference CD for \$750 (plus shipping). Massachusetts delivery will include 6.25% sales tax.

Please send information on exhibiting and opportunities to present workshops.

PAYMENT INFORMATION

Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.

Invoice me, but reserve my space with credit card information listed below.

Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, please check with CHI beforehand for space availability.

Please charge: AMEX (15 digits) Visa (13-16 digits) MasterCard (16 digits)
Card # _____ Expiration Date _____

Cardholder _____

Signature _____

Cardholder's Address (if different from above) _____

City/State/Postal Code _____

Country _____

Please refer to the Registration Code below:

Present a Poster and Save \$50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions.

To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by **September 22, 2010**. Register online, or by phone, fax or mail. Indicate that you would like to present a poster and you will receive abstract submission instructions via email.

Title _____

Yes! I would like to receive a FREE eNewsletter subscription to: **Weekly Update** The latest industry news, commentary and highlights from Bio. IT World. www.chimedialogroup.com

CHI Insight Pharma Reports

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets. For a detailed list of reports, visit InsightPharmaReports.com, or contact Rose LaRaia, rlaraia@healthtech.com, 781-972-5444.

Barnett Educational Services

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit www.barnettinternational.com.

Additional Registration Details

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Group Discounts

Special rates are available for multiple attendees from the same organization.

Contact **David Cunningham at 781-972-5472** to discuss your options and take advantage of the savings.

Handicapped Equal Access

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

Substitution/Cancellation Policy

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization.
- Credit your registration to another Cambridge Healthtech Institute program.
- Request a refund minus a \$100 processing fee per conference.
- Request a refund minus the cost (\$750) of ordering a copy of the CD.

NOTE: Cancellations will only be accepted up to two weeks prior to the conference. Program and speakers are subject to change.

Video and/or audio recording of any kind is prohibited onsite at all CHI events.